Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Extension of Olesoxime in ALS
NCT01285583Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2010
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of olesoxime in amyotrophic lateral sclerosis (ALS), sponsored by Roche. Primary endpoint: Safety assessment at 15 months. Started Oct 2010; status: completed.
02
Drugs
olesoxime
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT01285583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01285583.